PRAMEF18

Across TCGA pan-cancer cohorts, PRAMEF18 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated PRAMEF18 data layer compared with 3 for mutation status.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher PRAMEF18 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF18 expression acts as an unfavorable survival marker, although some lineages such as OV and BLCA show a favorable association.

KIRC, UCS, and MESO are the cancer types where PRAMEF18 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Tertile	III,IV	0.173	0.518	.001	102	view →
UCS	OS	Tertile	All	0.256	0.606	.020	90	view →
MESO	OS	Tertile	IV	0.036	0.602	<.001	72	view →
SKCM	OS	Tertile	III,IV	0.493	0.727	.007	54	view →
BRCA	OS	Tertile	II,III,IV	0.794	0.917	<.001	42	view →
LUAD	DFS	Tertile	IV	0.342	0.893	<.001	36	view →
ACC	OS	Tertile	All	0.133	0.686	.004	36	view →
CESC	DFS	Tertile	II,III,IV	0.462	0.793	.002	18	view →
GBM	OS	Tertile	All	0.152	0.418	.035	9	view →
DLBC	DFS	Tertile	III,IV	0.137	0.761	.014	9	view →
OV	OS	Tertile	IV	0.608	0.332	.035	6	view →
BLCA	DFS	Tertile	III,IV	0.555	0.158	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

PRAMEF18–KIRC (DFS)

Open the KIRC breakdown →